Apitegromab Aids in Healthier Weight Reduction for GLP-1 Agonists Users in the EMBRAZE Study (SRRK's Study)
Pumped-up Precis:
With a 13% surge in premarket trading to $35.18, Scholar Rock's (SRRK) shares are on fire, following the positive outcomes from the EMBRAZE trial. This study had Scholar Rock's lead drug candidate Apitegromab teaming up with Lilly's Zepbound, a GLP-1 receptor agonist, to combat obesity and overweight issues.
GLP-1 therapies, like Zepbound, have been effective in managing obesity and cardiometabolic disorders, but they often lead to unwanted muscle loss. But EMBRAZE has turned a corner. Apitegromab in conjunction with a GLP-1 receptor agonist seems to tackle the challenge of muscle loss during weight management.
The results showed that, compared to Zepbound alone, a combination therapy of Apitegromab with Zepbound preserved an additional 4.2 lbs (1.9 kg) or 54.9% of lean mass over 24 weeks, resulting in higher-quality weight loss. The combination treatment was generally well-tolerated by the participants.
Further data from the study will be unveiled at upcoming medical congresses.
Apitegromab by Scholar Rock is currently in FDA review for the treatment of Spinal Muscular Atrophy, with a decision due on September 22, 2025.
SMA is a rare, genetic neuromuscular disease characterized by motor neuron loss, muscle atrophy, and progressive weakness. It affects approximately 30,000 to 35,000 people across the United States and Europe.
Scholar Rock first made headlines on September 27, 2023, when the stock was trading at $6.45. We sounded the alarm again on October 7, 2024, after the stock spiked to $26.34.
In the last year, SRRK has traded between $6.76 and $46.98, closing yesterday's session at $31.15, down 3.05%.
For feedback, reach out at editorial@our website.
Business Byte:
- Stocks
- Scholar Rock
- SRRK
- EMBRAZE trial
- Apitegromab
- Zepbound
- Obesity treatment
- Muscle preservation
- Spinal Muscular Atrophy (SMA)
- The combination of Scholar Rock's Apitegromab with Lilly's Zepbound, as seen in the EMBRAZE trial, shows promise in the health-and-wellness sector, particularly for weight-management, by preserving lean mass during weight loss and combating obesity.
- Scholar Rock, represented by the ticker symbol SRRK, saw a significant 13% surge in premarket trading, reflecting increased investor interest in their weight-management and health-and-wellness initiatives, such as the EMBRAZE trial for obesity treatment.
- Beyond weight management, Apitegromab by Scholar Rock is also under FDA review for the treatment of Spinal Muscular Atrophy (SMA), a rare neuromuscular disease, highlighting the company's diverse focus on both health-and-wellness and science, as well as its potential financial growth in the biotech sector.
){kind=link}